way that muromonab-cd acts on the body
chance
effects
years after the medicine
delayed effects
certain types of cancer
lymphomas
skin cancers
possible effects
doctor
following side effects
medical attention
following side effects
taking
doctor
nurse
taking
drug
side effects
medical attention
following side effects
doctor
general
side effects of muromonab cd
acute clinical syndrome
cytokine release syndrome
crs
crs
release of cytokines
activated t cells
illness
including fever
spiking
degrees fahrenheit
chills
rigors
headache
nausea
vomiting
diarrhea
malaise
arthralgias
myalgias
weakness
manifestations
pulmonary edema
hemodynamic instability
shock
respiratory arrest
cardiac arrest
crs
first few doses of muromonab cd onset of symptoms
minutes after the first dose
symptoms
release of cytokines
including tumor necrosis factor
gamma interferon
interleukin
interleukin
interleukin
interleukin
granulocyte colony stimulating factor
t cells
following binding of muromonab cdpretreatment with mg/kg methylprednisolone sodium succinate
hours
mg hydrocortisone sodium succinate minutes after administration of the first dose of muromonab cd
severity of symptoms
crs
data
conflicting
other agents
benefit
indomethacin
heparin
pentoxifylline
experimental anti-tnf monoclonal antibodies
patients
increased risk for serious complications
crs
unstable angina
recent myocardial infarction
symptomatic ischemic heart disease
heart failure
pulmonary edema
intravascular volume overload
depletion
cerebrovascular disease
septic shock
history of seizures
cardiovascular
side effects
patients
receiving muromonab cd for prophylaxis of allograft rejection
patients
receiving muromonab cd for reversal of rejection
tumor necrosis factor
pathogenesis of the cardiovascular side effects
study
involving patients
muromonab cd mg per day
days for renal allograft rejection
diastolic blood pressures
mmhg
day
patients
day
diastolic pressures
mmhg
patients
heart rate
beats per minute on day
change
day
significant changes in blood pressure
heart rate
day
increase in blood pressure
hours on day
hours on day
thrombosis of allografts
other vascular beds
therapy with muromonab cd
study of renal allograft recipients
receiving muromonab cd
patients
intragraft thromboses
weeks of transplantation
elevated prothrombin fragments
control group
tumor necrosis factor
endothelial cell activation
playing
role in the thrombotic events
cardiovascular
side effects
hypertension
hypotension
chest pain
angina
tachycardia
bradycardia
hemodynamic instability
cardiac arrest
severe hypotension
shock
heart failure
cardiovascular collapse
ventricular dysfunction
arrhythmias
addition
thrombotic events within main graft vessels
pulmonary edema
patients in early studies
patients
pretreatment period
restrictions against use in patients
volume
greater increase in body weight during the week
muromonab cd treatment
occurrence of pulmonary edema
cases of pulmonary edema in euvolemic patients
increased pulmonary vascular permeability
reduced left ventricular compliance
contractility
additional risk factors
mechanism
tumor necrosis factor-alpha
complement activation
pulmonary sequestration
activated granulocytes
use of muromonab cd
patients with volume overload
uncompensated heart failure
respiratory side effects
dyspnea
shortness of breath
bronchospasm
apnea
tachypnea
serious effects
including
pulmonary edema
respiratory distress syndrome
respiratory failure
muromonab cd therapy
aseptic meningitis
hours
first dose of muromonab cd
symptoms of fever
headache
nuchal rigidity
photophobia
cerebral spinal fluid findings
pleocytosis
elevated protein
negative cultures
symptoms
days
muromonab cd therapy
encephalopathy
cytokine encephalopathy
patients
confusion
hallucinations
seizures
obtundation
coma
blindness
cytokine encephalopathy
significant intervention
severe cases
discontinuation of the drug
permanent neurologic deficits
study
delayed graft function as a significant risk factor for the development of cytokine encephalopathy in patients
muromonab cd
nervous system
side effects
headache
mental status changes
more serious sequelae
seizures
cerebritis
aseptic meningitis
encephalopathy
hematologic side effects
pancytopenia
aplastic anemia
neutropenia
leukopenia
thrombocytopenia
lymphopenia
leukocytosis
disturbances in coagulation
graft vessel thromboses
elevations in prothrombin fragments
von willebrand
factor
been found following
first dose of muromonab cd tumor necrosis factor-alpha
mediator of muromonab cd-induced coagulopathy
oncologic side effects
development of new malignancies
particular concern in post-transplant patients
lymphoproliferative disorders
concern
lymphadenopathy
benign polyclonal b cell hyperplasia
b cell lymphomas
majority of lymphomas
months
following transplantation
time of diagnosis
reduction in doses of other immunosuppressants during muromonab cd therapy for reversal of rejection
risk of neoplastic disease
muromonab cd
patients with a history of hypersensitivity
murine-derived products
anti-mouse antibody titer
retreatment with muromonab cd
increased incidence of hypersensitivity reactions
caution
hypersensitivity side effects from muromonab cd
rash
pruritus
angioedema
anaphylaxis
addition
serum sickness
immune complex deposition
causing glomerulonephritis
vasculitis
temporal arteritis
eosinophilia
reversible renal dysfunction
cytokine nephropathy
transient increases in serum creatinine
blood urea nitrogen
study
serum creatinine
average of mg/dl
prerejection levels by the end of muromonab cd therapy
renal side effects
slight decline in renal function
transient increase in serum creatinine
blood urea nitrogen
addition
anuria
oliguria
delayed renal graft function
interstitial nephritis
abnormal urinalysis
gastrointestinal side effects
nausea/vomiting
diarrhea
severe requiring fluid management
addition
cases of bowel infarction
pancreatitis
other side effects
muromonab cd
blindness
anterior scleritis
vision
double vision
conjunctivitis
hearing loss
vertigo
tinnitus
vi
cranial nerve palsy
immunologic side effects
infections
muromonab cd therapy
result of immunosuppression
cytomegalovirus
herpes simplex
fungal infections
encountered infections during muromonab cd
immunosuppressive therapy
other infections
including
protozoal
several studies
increased risk of invasive cytomegalovirus infection in recipients of cmv-positive grafts
significant increase in morbidity
mortality
chest pain
irregular heartbeat
shortness of breath
wheezing
swelling of face
throat
diarrhea
dizziness or faintness
fever and chills
general feeling of discomfort
illness
headache
muscle
joint pain
nausea and vomiting
confusion
black, tarry stools
blood in urine
stools
convulsions (seizures)
cough or hoarseness
hallucinations
seeing
hearing
feeling things
itching or tingling
loss of hearing
vision
side pain
difficult urination
red spots on skin
skin rash
sores
ulcers
white spots on the lips
mouth
stiff neck
painful glands
tightness in the chest
trembling
shaking of hands
troubled breathing
unusual sensitivity of eyes
light
unusual bleeding
bruising
unusual tiredness
weakness
fever and chills